FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328116719> ?p ?o ?g. }

• W4328116719 endingPage "2806" @default.
• W4328116719 startingPage "2806" @default.
• W4328116719 abstract "The unusual and interesting architecture of the catalytic chamber of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) was recently explored using Cryogenic Electron Microscopy (Cryo-EM), which revealed the presence of two distinctive binding cavities within the catalytic chamber. In this report, first, we mapped out and fully characterized the variations between the two binding sites, BS1 and BS2, for significant differences in their amino acid architecture, size, volume, and hydrophobicity. This was followed by investigating the preferential binding of eight antiviral agents to each of the two binding sites, BS1 and BS2, to understand the fundamental factors that govern the preferential binding of each drug to each binding site. Results showed that, in general, hydrophobic drugs, such as remdesivir and sofosbuvir, bind better to both binding sites than relatively less hydrophobic drugs, such as alovudine, molnupiravir, zidovudine, favilavir, and ribavirin. However, suramin, which is a highly hydrophobic drug, unexpectedly showed overall weaker binding affinities in both binding sites when compared to other drugs. This unexpected observation may be attributed to its high binding solvation energy, which disfavors overall binding of suramin in both binding sites. On the other hand, hydrophobic drugs displayed higher binding affinities towards BS1 due to its higher hydrophobic architecture when compared to BS2, while less hydrophobic drugs did not show a significant difference in binding affinities in both binding sites. Analysis of binding energy contributions revealed that the most favorable components are the ΔEele, ΔEvdw, and ΔGgas, whereas ΔGsol was unfavorable. The ΔEele and ΔGgas for hydrophobic drugs were enough to balance the unfavorable ΔGsol, leaving the ΔEvdw to be the most determining factor of the total binding energy. The information presented in this report will provide guidelines for tailoring SARS-CoV-2 inhibitors with enhanced binding profiles." @default.
• W4328116719 created "2023-03-22" @default.
• W4328116719 creator A5008929870 @default.
• W4328116719 creator A5015603070 @default.
• W4328116719 creator A5021219358 @default.
• W4328116719 creator A5038750075 @default.
• W4328116719 creator A5052507777 @default.
• W4328116719 creator A5054035889 @default.
• W4328116719 creator A5065235637 @default.
• W4328116719 creator A5069023191 @default.
• W4328116719 creator A5073541188 @default.
• W4328116719 creator A5075082365 @default.
• W4328116719 creator A5080381111 @default.
• W4328116719 creator A5088960433 @default.
• W4328116719 date "2023-03-20" @default.
• W4328116719 modified "2023-10-05" @default.
• W4328116719 title "The Unusual Architecture of RNA-Dependent RNA Polymerase (RdRp)’s Catalytic Chamber Provides a Potential Strategy for Combination Therapy against COVID-19" @default.
• W4328116719 cites W1969046853 @default.
• W4328116719 cites W1991741354 @default.
• W4328116719 cites W2020828286 @default.
• W4328116719 cites W2031168104 @default.
• W4328116719 cites W2035266068 @default.
• W4328116719 cites W2043855224 @default.
• W4328116719 cites W2046229956 @default.
• W4328116719 cites W2047544230 @default.
• W4328116719 cites W2106140689 @default.
• W4328116719 cites W2132629607 @default.
• W4328116719 cites W2134967712 @default.
• W4328116719 cites W2142868265 @default.
• W4328116719 cites W2147993766 @default.
• W4328116719 cites W2245937241 @default.
• W4328116719 cites W2332712348 @default.
• W4328116719 cites W2902764545 @default.
• W4328116719 cites W2914796231 @default.
• W4328116719 cites W2995552435 @default.
• W4328116719 cites W3010062253 @default.
• W4328116719 cites W3011848620 @default.
• W4328116719 cites W3015429854 @default.
• W4328116719 cites W3016143592 @default.
• W4328116719 cites W3022734398 @default.
• W4328116719 cites W3032133680 @default.
• W4328116719 cites W3043789997 @default.
• W4328116719 cites W3045003495 @default.
• W4328116719 cites W3133499696 @default.
• W4328116719 cites W3135320956 @default.
• W4328116719 cites W3181281182 @default.
• W4328116719 cites W3217141529 @default.
• W4328116719 cites W4214520590 @default.
• W4328116719 cites W4221034817 @default.
• W4328116719 cites W4280536890 @default.
• W4328116719 cites W4280578005 @default.
• W4328116719 cites W4281489107 @default.
• W4328116719 cites W4283832578 @default.
• W4328116719 doi "https://doi.org/10.3390/molecules28062806" @default.
• W4328116719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36985777" @default.
• W4328116719 hasPublicationYear "2023" @default.
• W4328116719 type Work @default.
• W4328116719 citedByCount "2" @default.
• W4328116719 countsByYear W43281167192023 @default.
• W4328116719 crossrefType "journal-article" @default.
• W4328116719 hasAuthorship W4328116719A5008929870 @default.
• W4328116719 hasAuthorship W4328116719A5015603070 @default.
• W4328116719 hasAuthorship W4328116719A5021219358 @default.
• W4328116719 hasAuthorship W4328116719A5038750075 @default.
• W4328116719 hasAuthorship W4328116719A5052507777 @default.
• W4328116719 hasAuthorship W4328116719A5054035889 @default.
• W4328116719 hasAuthorship W4328116719A5065235637 @default.
• W4328116719 hasAuthorship W4328116719A5069023191 @default.
• W4328116719 hasAuthorship W4328116719A5073541188 @default.
• W4328116719 hasAuthorship W4328116719A5075082365 @default.
• W4328116719 hasAuthorship W4328116719A5080381111 @default.
• W4328116719 hasAuthorship W4328116719A5088960433 @default.
• W4328116719 hasBestOaLocation W43281167191 @default.
• W4328116719 hasConcept C104317684 @default.
• W4328116719 hasConcept C107824862 @default.
• W4328116719 hasConcept C121332964 @default.
• W4328116719 hasConcept C12554922 @default.
• W4328116719 hasConcept C170493617 @default.
• W4328116719 hasConcept C181199279 @default.
• W4328116719 hasConcept C185544564 @default.
• W4328116719 hasConcept C185592680 @default.
• W4328116719 hasConcept C2776182878 @default.
• W4328116719 hasConcept C2776449523 @default.
• W4328116719 hasConcept C2780283098 @default.
• W4328116719 hasConcept C3018795828 @default.
• W4328116719 hasConcept C55493867 @default.
• W4328116719 hasConcept C67705224 @default.
• W4328116719 hasConcept C71240020 @default.
• W4328116719 hasConcept C82381507 @default.
• W4328116719 hasConcept C86803240 @default.
• W4328116719 hasConcept C90260826 @default.
• W4328116719 hasConcept C93282013 @default.
• W4328116719 hasConceptScore W4328116719C104317684 @default.
• W4328116719 hasConceptScore W4328116719C107824862 @default.
• W4328116719 hasConceptScore W4328116719C121332964 @default.
• W4328116719 hasConceptScore W4328116719C12554922 @default.
• W4328116719 hasConceptScore W4328116719C170493617 @default.
• W4328116719 hasConceptScore W4328116719C181199279 @default.

• next